

### IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A method of treating a human patient suffering from an ocular allergy, comprising:

administering to said patient an ophthalmic composition ~~containing~~ comprising from about 0.01% to about 0.1% of a macrolide compound.

Claim 2 (Currently Amended): A method according to claim 1, wherein said ocular allergy is allergic conjunctivitis.

Claim 3 (Currently Amended): A method according to claim 1 or 2, wherein said composition ~~contains~~ comprises from about 0.03% to about 0.06% of said macrolide compound.

Claim 4 (Currently Amended): A method according to claim 3, wherein said ~~macrolide compound~~ ophthalmic composition ~~contains~~ comprises about 0.03% of said macrolide compound.

Claim 5 (Currently Amended): A method according to claim 1, wherein said macrolide compound is FK506.


Claim 6 (Currently Amended): A method according to claim 1, wherein said ophthalmic composition is an eye drop.

Claim 7 (Currently Amended): A method according to claim 6, wherein said eye drop further ~~contains~~ comprises polyvinyl alcohol.

Claim 8 (Currently Amended): A method according to claim 7, wherein said eye drop ~~contains~~ comprises about 0.03% of said macrolide compound.

Claim 9 (Original): A method according to claim 8, wherein said eye drop is administered from about one to about 4 times per day.

Claim 10 (Currently Amended): A method according to ~~any of claims 1 to 9~~ claim 1, wherein said macrolide compound is a compound having the following formula (I) or a pharmaceutically acceptable salt thereof:



wherein adjacent pairs of  $R^1$  and  $R^2$ ,  $R^3$  and  $R^4$ , and  $R^5$  and  $R^6$  each independently

- consist of two adjacent hydrogen atoms, wherein  $R^2$  is optionally alkyl, or
- form another bond optionally between carbon atoms binding with the members of said pairs;

$R^7$  is hydrogen atom, hydroxy, alkyloxy or protected hydroxy, or may form oxo with  $R^1$ ;

$R^8$  and  $R^9$  each independently show hydrogen atom or hydroxy;

$R^{10}$  is hydrogen atom, alkyl, alkyl substituted by one or more hydroxy, alkenyl, alkenyl substituted by one or more hydroxy or alkyl substituted by oxo;

X is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group of the formula  $-\text{CH}_2\text{O}-$ ;

Y is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group of the formula  $\text{N}-\text{NR}^{11}\text{R}^{12}$  or  $\text{N}-\text{OR}^{13}$ ;


$R^{11}$  and  $R^{12}$  each independently show hydrogen atom, alkyl, aryl or tosyl;

$R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{22}$  and  $R^{23}$  each independently show hydrogen atom or alkyl;

$R^{24}$  is an optionally substituted ring that may contain one or more hetero atom(s); and

n is 1 or 2.

Claim 11 (Original): A method according to claim 10, wherein said macrolide compound has the following structure:



Claim 12 (Currently Amended): An ophthalmic composition for treatment of ocular allergy ~~containing~~ comprising from about 0.01% to about 0.1% of a macrolide compound.

Claim 13 (Currently Amended): An ophthalmic composition according to claim 12, wherein said ocular allergy is allergic conjunctivitis.

Claim 14 (Currently Amended): An ophthalmic composition according to claim 12 or 13, comprising ~~which contains~~ from about 0.03% to about 0.06% of said macrolide compound.

Claim 15 (Currently Amended): An ophthalmic composition according to claim 14, comprising ~~which contains~~ about 0.03% of said macrolide compound.

Claim 16 (Currently Amended): An ophthalmic composition according to claim 12, wherein said macrolide compound is FK506.


Claim 17 (Currently Amended): An ophthalmic composition according to claim 12, which is an eye drop.

Claim 18 (Currently Amended): An ophthalmic composition according to claim 17, wherein said eye drop further ~~contains~~ comprises polyvinyl alcohol.

Claim 19 (Currently Amended): An ophthalmic composition according to claim 18, wherein said eye drop ~~contains~~ comprises about 0.03% of said macrolide compound.

Claim 20 (Original): An ophthalmic composition according to claim 19, wherein said eye drop is administered from about one to about 4 times per day.

Claim 21 (Currently Amended): An ophthalmic composition according to ~~any of~~ ~~claims 12 to 20~~ claim 12, wherein said macrolide compound is a compound having the following formula (I) or a pharmaceutically acceptable salt thereof:



wherein adjacent pairs of  $R^1$  and  $R^2$ ,  $R^3$  and  $R^4$ , and  $R^5$  and  $R^6$  each independently

- consist of two adjacent hydrogen atoms, wherein  $R^2$  is optionally alkyl, or
- form another bond optionally between carbon atoms binding with the members of said pairs;

$R^7$  is hydrogen atom, hydroxy, alkyloxy or protected hydroxy, or may form oxo with  $R^1$ ;

$R^8$  and  $R^9$  each independently show hydrogen atom or hydroxy;

$R^{10}$  is hydrogen atom, alkyl, alkyl substituted by one or more hydroxy, alkenyl, alkenyl substituted by one or more hydroxy or alkyl substituted by oxo;

X is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group of the formula  $-\text{CH}_2\text{O}-$ ;

Y is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group of the formula  $\text{N}-\text{NR}^{11}\text{R}^{12}$  or  $\text{N}-\text{OR}^{13}$ ;

$\text{R}^{11}$  and  $\text{R}^{12}$  each independently show hydrogen atom, alkyl, aryl or tosyl;

$\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  each independently show hydrogen atom or alkyl;

$\text{R}^{24}$  is an optionally substituted ring that may contain one or more hetero atom(s); and  
n is 1 or 2.

Claims 22-33 (Canceled).

Claim 34 (Currently Amended): A commercial package comprising the ophthalmic composition of ~~any of claims 12 to 22~~ claim 12 and a written matter associated therewith, the written matter stating that the composition can or should be used for allergic conjunctivitis.